The Mumbai-based Wyeth Ltd will launch some of its global OTC brands in the country in the coming months, according to senior officials of the company. The brands that are likely to be launched include Robitussin and Dimetapp (respiratory diseases), Centrum (vitamins) and Advil (analgesic).

The company will manufacture these products in the country through third party sources, and will price them on par with the market, it is learnt.

"India, with its huge market, holds good potential for OTC products. We will be adding to the Indian market new products every year," said David C Giffin, senior vice president, (Asia/Pacific and Latin America), Wyeth Consumer Healthcare.

Wyeth has a global OTC market of $ 7 million. The company's OTC stable in the country is also small with Anacin tablets & pain balm, the only major OTC products marketed in the country.

Meanwhile, in the non-OTC segment, the company has plans to launch a slew of innovative products in the near future, which will include even the patented ones. According to Ranga Iyer, managing director, Wyeth India, new products will contribute to 50 per cent of the company's total sales by 2008.

During the current year, Wyeth India will launch low dosage variations of its conjugated estrogen tablets Premarin and Premelle 2.5.

The company launched Embrel (Rhumatoid arthritis) and Rapamune last year. Embrel is an injectable TNF alpha-blocker, a key factor for the cause of arthritis and is priced at Rs 7,000 per injection.

In its recently concluded Annual General Meeting, Wyeth India announced a 100 per cent dividend for its shareholders.